Hugo Senra1, Konstantinos Balaskas2, Neda Mahmoodi3, Tariq Aslam4. 1. Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom. 2. Manchester Royal Eye Hospital, Central Manchester Foundation Trust, Manchester, United Kingdom. 3. Faculty of Health and Social Sciences, School of Psychology, Leeds Beckett University, Leeds, United Kingdom. 4. Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; Manchester Royal Eye Hospital, Central Manchester Foundation Trust, Manchester, United Kingdom. Electronic address: Tariq.Aslam@cmft.nhs.uk.
Abstract
PURPOSE: To investigate detailed patient experiences specific to receiving vascular endothelial growth factor inhibitors (anti-VEGF) for wet age-related macular degeneration (wAMD), and to acquire a snapshot of the frequency of clinically significant levels of depression, anxiety, and posttraumatic stress among patients and levels of burden in patients' carers. DESIGN: Observational cross-sectional mixed-methods study. METHODS: Three hundred patients with wAMD receiving anti-VEGF treatment and 100 patient carers were recruited. Qualitative data on patients' experience of treatment were collected using a structured survey. Standardized validated questionnaires were used to quantify clinically significant levels of anxiety, depression, and posttraumatic stress, as well as cognitive function and carers' burden. RESULTS: Qualitative data showed that 56% of patients (n = 132) reported anxiety related to anti-VEGF treatment. The main sources of anxiety were fear of going blind owing to intravitreal injections and concerns about treatment effectiveness, rather than around pain. From validated questionnaires, 17% of patients (n = 52) showed clinical levels of anxiety and 12% (n = 36) showed clinical levels of depression. Depression levels, but not anxiety, were significantly higher in patients who received up to 3 injections compared with patients who received from 4 to 12 injections (analysis of variance [ANOVA] P = .027) and compared with patients who received more than 12 injections (ANOVA P = .001). CONCLUSIONS: Anti-VEGF treatment is often experienced with some anxiety related to treatment, regardless of the number of injections received. Clinical levels of depression seem to be more frequent in patients at early stages of anti-VEGF treatment. Strategies to improve patient experience of treatment and minimize morbidity are suggested. Crown
PURPOSE: To investigate detailed patient experiences specific to receiving vascular endothelial growth factor inhibitors (anti-VEGF) for wet age-related macular degeneration (wAMD), and to acquire a snapshot of the frequency of clinically significant levels of depression, anxiety, and posttraumatic stress among patients and levels of burden in patients' carers. DESIGN: Observational cross-sectional mixed-methods study. METHODS: Three hundred patients with wAMD receiving anti-VEGF treatment and 100 patient carers were recruited. Qualitative data on patients' experience of treatment were collected using a structured survey. Standardized validated questionnaires were used to quantify clinically significant levels of anxiety, depression, and posttraumatic stress, as well as cognitive function and carers' burden. RESULTS: Qualitative data showed that 56% of patients (n = 132) reported anxiety related to anti-VEGF treatment. The main sources of anxiety were fear of going blind owing to intravitreal injections and concerns about treatment effectiveness, rather than around pain. From validated questionnaires, 17% of patients (n = 52) showed clinical levels of anxiety and 12% (n = 36) showed clinical levels of depression. Depression levels, but not anxiety, were significantly higher in patients who received up to 3 injections compared with patients who received from 4 to 12 injections (analysis of variance [ANOVA] P = .027) and compared with patients who received more than 12 injections (ANOVA P = .001). CONCLUSIONS: Anti-VEGF treatment is often experienced with some anxiety related to treatment, regardless of the number of injections received. Clinical levels of depression seem to be more frequent in patients at early stages of anti-VEGF treatment. Strategies to improve patient experience of treatment and minimize morbidity are suggested. Crown
Authors: Shrirang V Ranade; Mark R Wieland; Tammy Tam; Jennifer C Rea; Judit Horvath; Aaron R Hieb; Weitao Jia; Lori Grace; Giulio Barteselli; Jay M Stewart Journal: Drug Deliv Date: 2022-12 Impact factor: 6.819
Authors: Eva K Fenwick; Ester P X Lee; Ryan E K Man; Kam Chun Ho; Raymond P Najjar; Dan Milea; Kelvin Y C Teo; Anna C S Tan; Shu Yen Lee; Ian Yew San Yeo; Gavin S W Tan; Ranjana Mathur; Tien Yin Wong; Chui Ming Gemmy Cheung; Ecosse L Lamoureux Journal: Qual Life Res Date: 2021-09-25 Impact factor: 4.147
Authors: Hilde P A van der Aa; Ger H M B van Rens; Frank D Verbraak; Machteld Bosscha; Marc A Koopmanschap; Hannie C Comijs; Pim Cuijpers; Ruth M A van Nispen Journal: BMJ Open Date: 2017-11-15 Impact factor: 2.692
Authors: Hilde Pa van der Aa; Ger Hmb van Rens; Frank D Verbraak; Machteld Bosscha; Hannie C Comijs; Ruth Ma van Nispen Journal: Ophthalmic Physiol Opt Date: 2021-05-29 Impact factor: 3.117